Emylcamate

Clinical data
ATC code	N05BC03 (WHO)
Legal status
Legal status	BR: Class C1 (Other controlled substances)[1]
Identifiers
IUPAC name 3-methyl-3-pentanol carbamate
CAS Number	78-28-4 Y
PubChem CID	6526
DrugBank	DB13572 Y
ChemSpider	6278 Y
UNII	KCJ747D3R4
KEGG	D07317 Y
ChEBI	CHEBI:134769
ChEMBL	ChEMBL2104208 Y
CompTox Dashboard (EPA)	DTXSID40228645
ECHA InfoCard	100.001.002
Chemical and physical data
Formula	C7H15NO2
Molar mass	145.202 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(OC(C)(CC)CC)N
InChI InChI=1S/C7H15NO2/c1-4-7(3,5-2)10-6(8)9/h4-5H2,1-3H3,(H2,8,9) Y Key:SLWGJZPKHAXZQL-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Emylcamate (marketed as Striatran by Merck) is an anxiolytic and muscle relaxant. It was patented in the US in 1961 (US Patent 2,972,564) and advertised for the treatment of anxiety and tension. It was claimed to be superior to meprobamate, which would eventually replace emylcamate.

A study of the drug's effects in mice was done in 1959. It concluded that at 50 mg/kg emylcamate gave a 63% decrease in motor activity compared with meprobamate's 32% decrease, a doubling in effective potency. The therapeutic index in mice was also established:

Emylcamate also has a faster intra-parenteral onset than meprobamate, 3 minutes compared with 35.^[2]